The funds will support Phase 2 testing of a drug the company believes to be able to safety home in on AMPA receptors, an ...

The U.K.-based biotech is set to enter mid-stage studies for its depression drug this year, while two other GABAA modulators ...

A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in ...

Based on evidence from research on the receptors’ function in the brain and the drugs that can activate or inhibit them, the authors propose possible mechanisms by which GABA-modulating ...

The financing has been billed as the most significant commercial investment into Welsh research to date, and will help Draig ...

Based on evidence from research on the receptors’ function in the brain and the drugs that can activate or inhibit them, the authors propose possible mechanisms by which GABA-modulating ...

"All of these drugs target GABA-A receptors, and we had some clues that these receptors might be affected in DM, because of years of reports on post-operative anesthesia complications," says ...

Gamma-aminobutyric acid (GABA) is a neurotransmitter, or chemical messenger, in the brain. It has a calming effect by blocking certain signals in the nervous system. The brain produces and ...

Depression, characterized by persistent sadness, hopelessness and a lack of interest in previously enjoyed activities, is one of the most common mental health disorders. Recent estimates by the World ...

"All of these drugs target GABA-A receptors, and we had some clues that these receptors might be affected in DM, because of years of reports on post-operative anesthesia complications," says ...